CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer

CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer#CStone #Submits #Application #European #Medicines #Agency #Indication #Sugemalimab #Stage #III #NonSmall #Cell #Lung #Cancer